News - Medivir


Current filters:


Popular Filters

Positive new Ph III data from once-daily simeprevir presented at APASL


Encouraging new Phase III data for the once-daily protease inhibitor simeprevir (trade name Olysio in…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalResearchsimeprevir

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA


It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

Unanimous FDA panel backing for Janssen’s simeprevir for hep C


Janssen announced yesterday that the FDA's Antiviral Drugs Advisory Committee unanimously recommended…

Anti-viralsJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevir

Ferrer and Medivir join forces on Adasuve for Nordic markets


Sweden’s Medivir (Nasdaq OMX: MVIR) and privately-held Spanish drugmaker Ferrer Internacional have…

AdasuveAlexza PharmaceuticalEuropeFerrer InternacionalLicensingMedivirNeurologicalPharmaceutical

Medivir and Daewoong drop hep C drug candidate


Swedish infectious disease drug developer Medivir (STO:MVIR-B) said on Friday (September 6) that it has…


Clinical updates at ROI meeting on GSK's dolutegravir and Medivir's simeprevir


UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drug major Shionogi (TYO: 4507) reported interim…


Bristol-Myers expands hepatitis C accord with Medivir and Janssen


Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Bristol-Myers links with Tibotec for Ph II combination study in hepatitis C patients


US drug major Bristol-Myers Squibb (NYSE: BMY) has entered into a clinical collaboration agreement with…

Anti-viralsBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirPharmaceuticalResearchTibotec

Medivir’s new subsid BioPhausia AB sells generics business to Bluefish


Huddinge, Sweden-based infectious disease research specialist Medivir (OMX: MVIR) says it recently-acquired…

BioPhausiaBluefish PharmaceuticalsGenericsMedivirMergers & Acquisitions

Back to top